Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorWeill Cornell Medical College in Qatar
About this trial
The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.
Eligibility criteria
Qualifiers
Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year)
Age ≥18 and less than 60 years old
Living in a single residence (home, apartment) located anywhere in Qatar
Waist circumference ≥102 cm if male and ≥88 cm if female
Disqualifiers
Pregnancy (self-reported)
Screening visit urine positive for cotinine (NicAlert >100 ng/mL)
Living with an active smoker who smokes indoors (by self-report)
High risk conditions that prohibit allowing home BP to be >130/80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate < 60 ml/min)
Trial design
Treatments tested in this trial
- Air cleaners with HEPA filter
- Air cleaners without HEPA filter
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Weill Cornell Medical College in Qatar
Lead sponsor
Hamad Medical Corporation
Collaborator
Case Western Reserve University
Collaborator
Source ClinicalTrials.gov